Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
Gilead agrees $21bn buyout of Immunomedics
In May, Gilead also announced its intent to partner with Arcus Biosciences on the development and commercialisation of next-generation cancer immunotherapies.
Latest news
-
AbbVie signs immunotherapy pact with I-Mab worth $2bn
Focus of deal is anti-CD47 monoclonal antibody lemzoparlimab. AbbVie has bulked up its immunotherapy pipeline after signing a deal worth $2bn for rights to Shanghai-based I-Mab’s
-
Nestlé is set to acquire Aimmune in deal worth $2.6bn
allergy. The oral immunotherapy is comprised of defatted peanut flour that is sprinkled over food and given in small but gradually increasing amounts over a six-month period, with the aim
-
BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme
Agreement will focus on development in oncology and haematology. Bristol Myers Squibb (BMS) has inked a deal with Dragonfly Therapeutic for an exclusive license to its interleukin-12 immunotherapy programme. ... So far, IL-12 as a target in immunotherapy
-
Seres’ microbiome-based therapy hits the mark in phase 3
In March, Seres received funding from AstraZeneca for research expenses associated with a project exploring how the bacteria in the gut can affect, and possibly enhance, the effect of cancer immunotherapies. ... This includes research into Seres’ phase
-
Bristol-Myers Squibb’s revenues rise on Celgene acquisition
Sales of immunotherapy Opdivo decreased due to COVID-19 impact. Bristol-Myers Squibb has posted better-than-expected results in the second quarter of the year, with shares in the company ... One concerning caveat among the otherwise positive results was
More from news
Approximately 97 fully matching, plus 503 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of autologous T cells genetically modified (via lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR).
-
Pharma funding and M&A in 2020
Indeed, 2019 was notable for Bristol-Myers Squibb’s acquisition of Celgene (which at a stroke bolstered its immunotherapy and oncology departments), as well as AbbVie’s acquisition of Allergan for ... Indeed, a key theme of the deals I have mentioned
-
It started with a miss
However, we’re now moving into areas like immunotherapy and are on the edge of amazing innovations that will deliver great outcomes for patients.
-
A snapshot of Microbiotica
An area of high interest is the discovery that responses to cancer immunotherapy are dependent on gut bacteria.
-
Rethinking trials: the pros and cons of protocol amendments
This view is shared by Chris Learn, who said immunotherapy studies are more prone to amendments than other types of research.
More from intelligence
Approximately 5 fully matching, plus 55 partially matching documents found.
Latest appointments
-
New hires at Crescendo, Healx and Galecto
He joins Galecto from eTheRNA immunotherapies, a Belgian mRNA immunotherapy company.
-
New hires at bluebird bio, BioNTech and Provention Bio
In his role as CCO at Provention, Hoitt will be responsible for the development and execution of the company’s global commercial strategy for its type 1 diabetes prevention immunotherapy
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.
-
BMS appoints new commercial leader, Davies joins Eisai and more
The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy. ... Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as
-
Industry appointments
Zelluna Immunotherapy appoints CSO. Norwegian biotech Zelluna Immunotherapy has named Namir Hassan as its chief scientific officer (CSO). ... antigen. Hassan’s new role, however, will see him manage and plan the next stages of development for the TCR
More from appointments
Approximately 2 fully matching, plus 45 partially matching documents found.
Latest from PMHub
-
In the precision medicine era, the line between products and services is blurred
CAR-T is a new individualised cancer immunotherapy that has taken precision medicine to a new level.
-
Precision paediatrics: Treating patients with CAR-T
SA: CAR-T cell therapy is an innovative immunotherapy that modifies the body’s own immune T-cells to start attacking cancer cells. ... Immunotherapy has been around for many years, but this is the first time that the patients’ own T-cells have been
-
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. ... OncoSec's lead immunotherapy platform – TAVO (tavokinogene
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
There is a strong unmet medical need for novel immunotherapy approaches such as TAVO. ... Presented at: Society for Immunotherapy of Cancer 33rd Annual Meeting; November 7–11, 2018; Washington, DC.
-
Lucid Group welcomes new magical talent and boosts their medical writing teams with hires in the US and UK
With three years’ healthcare communications experience, and a wealth of knowledge in epilepsy, immunotherapy and oncology Andrew comments, “I have had a very fulfilling first two months at Lucid; the team
More from PMHub
Approximately 11 fully matching, plus 15 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
